Chloroquine and Hydroxychloroquine could be an Available Weapons to Treat COVID-19 Associated Pneumonia

References (45)

1. 1 A Novel Coronavirus from Patients with Pneumonia in China, 2019 [DOI]
2. 2 A pneumonia outbreak associated with a new coronavirus of probable bat origin [DOI]
3. 3 SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor [DOI]
4. 4 Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia [DOI]
5. 5 Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding [DOI]
6. 6 A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster [DOI]
7. 7 Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation [DOI]
8. 8 The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2 [DOI]
9. 9 Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro [DOI]
10. 10 Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis [DOI]
11. 11 Epidemiology, Genetic Recombination, and Pathogenesis of Coronaviruses [DOI]
12. 12 In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) [DOI]
13. 13 Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies [DOI]
14. 14 Chloroquine is a potent inhibitor of SARS coronavirus infection and spread [DOI]
15. 15 The spike protein of SARS-CoV — a target for vaccine and therapeutic development [DOI]
16. 16 Effects of chloroquine on viral infections: an old drug against today's diseases [DOI]
17. 17 Virus-encoded proteinases and proteolytic processing in the Nidovirales [DOI]
18. 18 The SARS-coronavirus papain-like protease: Structure, function and inhibition by designed antiviral compounds [DOI]
19. 19 An updated estimation of the risk of transmission of the novel coronavirus (2019-nCov) [DOI]
20. 20 Repurposing of Clinically Developed Drugs for Treatment of Middle East Respiratory Syndrome Coronavirus Infection [DOI]
21. 21 In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine [DOI]
22. 22 Drug targets for corona virus: A systematic review [DOI]
23. 23 Differential Downregulation of ACE2 by the Spike Proteins of Severe Acute Respiratory Syndrome Coronavirus and Human Coronavirus NL63 [DOI]
24. 24 Mechanism of action of hydroxychloroquine as an antirheumatic drug [DOI]
25. 25 Targeting the Endocytic Pathway and Autophagy Process as a Novel Therapeutic Strategy in COVID-19 [DOI]
26. 26 Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model [DOI]
27. 27 Design and Synthesis of Hydroxyferroquine Derivatives with Antimalarial and Antiviral Activities [DOI]
28. 28 Comparison of the Antiviral Activity in vitro of some Non-steroidal Anti-inflammatory Drugs [DOI]
29. 29 Antihistaminics, local anesthetics, and other amines as antiviral agents. [DOI]
30. 30 Will novel virus go pandemic or be contained? [DOI]
31. 31 Classics in Chemical Neuroscience: Chlorpromazine [DOI]
32. 32 Covid-19: a puzzle with many missing pieces [DOI]
33. 33 Old Weapon for New Enemy: Drug Repurposing for Treatment of Newly Emerging Viral Diseases [DOI]
34. 34 An Algorithmic Approach to Diagnosis and Treatment of Coronavirus Disease 2019 (COVID-19) in Children: Iranian Expert’s Consensus Statement [DOI]
35. 35 Effect of chloroquine on the growth of animal viruses [DOI]
36. 36 Chloroquine intoxication [letter] [DOI]
37. 37 Hydroxychloroquine augments early virological response to pegylated interferon plus ribavirin in genotype‐4 chronic hepatitis C patients [DOI]
38. 38 The Food and Drug Administration [DOI]
39. 39 Analysis of interventional clinical research protocols related to coronavirus disease 2019 and future expectations [DOI]
40. 40 Advances of the clinical pharmacology of hydroxychloroquine sulfate [DOI]
41. 41 Current status and bottlenecks of global pharmaceutical developments against COVID-19
42. 42 Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases [DOI]
43. 43 Research and development on therapeutic agents and vaccines for covid-19 and related human coronavirus diseases [DOI]
44. 44 [Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia]. [DOI]
45. 45 Correction to: COVID-19: a novel coronavirus and a novel challenge for critical care [DOI]

Cited by 5

Showing 2 of 5 known citations — external sources report more than can currently be individually listed.

Related research

• COVID 19 Disease Caused by Coronavirus 2 (SARS-CoV-2) (Severe Acute Respiratory Syndrome) — shares topic coverage
• Assessment of Anxiety in Healthcare Providers Working in ICU during COVID-19 Pandemics — shares topic coverage
• Azithromycin and Hydroxychloroquine Accelerate Recovery of Outpatients with Mild/Moderate COVID-19 — shares topic coverage
• Elevated Levels of Lactate Dehydrogenase Predicts Poor Outcomes for Patients with COVID-19: A Review — shares topic coverage
• Addressing the Challenges of Containing Covid-19 Spread in a Rural, Poor Area in India: A Case Study — shares topic coverage